« Return to News | Awards & Advancement

AMRI announces executive leadership changes

Tuesday, September 10, 2013 10:01 AM

CRO Albany Molecular Research has announced Thomas E. D'Ambra, Ph.D., will retire as president and chief executive officer, effective Dec. 31. D'Ambra will be named non-executive chairman of the board of directors on the same date.

D'Ambra will be succeeded as by William S. Marth, currently non-executive chairman of the AMRI board, effective Jan. 1. Marth will remain a board member.

Marth joined AMRI’s board in June 2012. Formerly he was president and chief executive officer of Teva Americas, retiring from Teva in 2012. He is a senior advisor to Teva through the end of 2013. He was president and CEO of Teva North America from 2008 to 2010, president and CEO of Teva U.S. and executive vice president and vice president of sales and marketing for Teva U.S.

Marth led the respiratory, neuroscience, oncology and women's healthcare divisions, as well as Latin America and Canada. He was a member of Teva's global executive management team and Teva Americas' board from 2007 until 2013. He brings global experience in strategic planning, investor relations, R&D, supply chain and regulatory. He was the architect of the $6.8 billion Cephalon and$7.4 billion Barr Laboratories acquisitions. Previously, he held various positions with the Apothecon division of Bristol-Myers Squibb.

Marth was chairman of the board of the Generic Pharmaceutical Association (GPhA) in 2008 and 2009 and the American Society for Health-System Pharmacists (ASHP) in 2010.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.